Literature DB >> 9393872

Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).

M Hamdane1, M H David-Cordonnier, J C D'Halluin.   

Abstract

The chimeric tyrosine kinase p210BCR-ABL is involved in the pathogenesis of chronic myelogenous leukemia. It transforms immature hematopoietic cells in vitro and abrogates IL-3-dependent growth. The mechanisms by which p210BCR-ABL mediates its oncogenicity are not well elucidated. Identifying transcription factors targeted by the chimeric protein may help to clarify these mechanisms. We have analysed the effect of p210BCR-ABL expression on NF-kappaB activity in DA1 cells (an IL-3-dependent murine myeloid progenitor cell line). A specific stimulation of NF-kappaB activity by kinase-active wild-type p210BCR-ABL has been evidenced by transcriptional activation assays. Electrophoretic mobility supershift assays revealed the presence of p65 protein (RelA) DNA binding activity in p210BCR-ABL transformed DA1 cells but not in parental DA1 cells. Activation of RelA in transformed DA1 cells may occur by protein stabilization. Experiments using oligonucleotides antisense to RelA showed that p210BCR-ABL transfected cells failed to survive after IL-3 removal. Moreover, inhibition of cellular growth was shown following treatment of p210BCR-ABL transformed DA1 cells by p65 antisense oligonucleotides. This study suggests that p65 NF-kappaB may be an effector for p210BCR-ABL and probably contributes to its induced transformation process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393872     DOI: 10.1038/sj.onc.1201411

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

Authors:  Fabio P S Santos; Hagop Kantarjian; David McConkey; Susan O'Brien; Stefan Faderl; Gautam Borthakur; Alessandra Ferrajoli; John Wright; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

2.  CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.

Authors:  Zhiqiang Wang; Ching-Cheng Chen; WenYong Chen
Journal:  Stem Cells       Date:  2015-10-15       Impact factor: 6.277

3.  Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Stéphane Flamant; William Ritchie; Joëlle Guilhot; Jeff Holst; Marie-Laure Bonnet; Jean-Claude Chomel; François Guilhot; Ali G Turhan; John E J Rasko
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

Review 4.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

Review 5.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

6.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Authors:  Mo-Ying Hsieh; Richard A Van Etten
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

Review 7.  Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.

Authors:  Tetsuzo Tauchi; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 8.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

9.  Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.

Authors:  F Besançon; A Atfi; C Gespach; Y E Cayre; M F Bourgeade
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.

Authors:  Yuping Wang; Jie Chen; Lin Wang; Yuji Huang; Ye Leng; Guiying Wang
Journal:  Exp Ther Med       Date:  2013-01-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.